首页> 外文OA文献 >PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY)

【2h】

PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY)

机译：PCN9比例风险（PH）威布尔模型在分析曲妥珠单抗（TZ）耐药性ERBB2 +（HER2 +）转移性乳腺癌（MBC）患儿的无进展生存率（PFS）和总生存率（OS）方面的有效性C）仅卡西他滨（仅C）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Sofrygin O; Delea T; Tappenden P; Karnon J; Amonkar MM; Walker M;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. 2135 POSTER Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with ErbB2+ (HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective [J] . T.E.Delea, P.Tappenden, O.Sofrygin, European Journal of Cancer Supplements . 2007,第4期

机译：2135事前对英国（UK）国家卫生署接受过曲妥珠单抗（TZ）治疗的ErbB2 +（HER2 +）转移性乳腺癌（MBC）妇女的拉帕替尼联合卡培他滨（L + C）的成本效益（CE）（NHS）观点
2. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. [J] . Zhou X, Cella D, Cameron D Breast cancer research and treatment. . 2009,第3期

机译：拉帕替尼加卡培他滨与单用卡培他滨治疗HER2 +（ErbB2 +）转移性乳腺癌：生活质量评估。
3. 2140 POSTER A comparison of lapatinib plus capecitabine versus capecitabine for quality-adjusted survival in metastatic breast cancer (MBC): A QTWiST analysis [J] . B.Sherrill, A.Allshouse, M.M.Amonkar, European Journal of Cancer Supplements . 2007,第4期

机译：2140海报拉帕替尼联合卡培他滨与卡培他滨治疗转移性乳腺癌（MBC）质量调整生存率的比较：QTWiST分析
4. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised open-label phase 3 trial [O] . Véronique Diéras, David Miles, Sunil Verma, -1

机译：曲妥珠单抗Emtansine与卡培他滨加拉帕替尼治疗先前治疗过的HER2阳性晚期乳腺癌（EMILIA）的患者：一项随机开放标签的3期临床试验的最终总体生存率的描述性分析
5. PCN59 COST EFFECTIVENESS ANALYSIS OF LAPATINIB/CAPECITABINE (LC) VERSUS TRASTUZUMAB/CAPECITABINE (TC) IN PATIENTS WITH METASTATIC BREAST CANCER ERBB2+ AFTER PROGRESSION TO THE FIRST SCHEME OF TRASTUZUMAB [O] . Anaya P., Aldaco F. 2011

机译：拉帕替尼/卡培他滨（LC）相对曲妥珠单抗/卡培他滨（TC）在转移性曲妥珠单抗进展后的患者中的PCN59成本效益分析

PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY)

著录项

相似文献

相关主题

期刊订阅